☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Eli Lilly
Eli Lilly Highlights 1 Year Analysis from the P-III (VIVID-1) Trial of Mirikizumab for Treating Crohn's Disease at UEG Week 2024
October 15, 2024
PharmaShots' Key Highlights of Third Quarter 2024
October 1, 2024
Eli Lilly's Kisunla (Donanemab-azbt) Receives the MHLW’s Approval for Treating Early Symptomatic Alzheimer's Disease (AD)
September 25, 2024
Eli Lilly’s Ebglyss (L ebrikizumab-lbkz) Receives the US FDA’s Approval for Treating Moderate-to-Severe Atopic Dermatitis
September 16, 2024
Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes...
September 11, 2024
Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes
September 6, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.